CEACAM5 and gastric cancer: In a meta-analysis of the remaining seven trials, the results suggested that the CEA+ patients with gastric cancer had a higher mortality risk than the CEA- patients (HR 1.940, 95% CI 1.563–2.408; Fig 2B).